Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination

12 Jul 2019

Abstract excerpt

Abstract The combined loss of CHD1 and MAP3K7 promotes aggressive prostate cancer by unknown mechanisms. Because both of these genes are lost genetically in prostate cancer, they cannot be directly targeted. We applied an established computational systems pharmacology approach (TRAP) to identify altered signaling pathways and associated druggable targets. We compared gene expression profiles of prostate cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FOXO transcription factor regulation
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31300540
DOI: 10.1158/1541-7786.mcr-18-1335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous RecombinationPMID 31300540Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read ↗

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.Semantic proximity Read ↗

The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.Semantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.Semantic proximity Read ↗

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate TumorsSemantic proximity Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate CancerSemantic proximity Read ↗

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.